drugset
drugset / Trial / NCT02022956

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956 ↗

Phase 1 Completed 8 enrolled Eisai Inc.
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old

Timeline

Start
2013-12
Primary completion
2013-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorcaserin Small molecule — Oral

Indications

No indication recorded.